Skip to main content
SpringerLink
Log in

Antisense Therapeutics for Tumor Treatment: The TGF-beta2 Inhibitor AP 12009 in Clinical Development Against Malignant Tumors

  • Chapter
Pancreatic Cancer

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 177))

Abstract

Overexpression of the cytokine transforming growth factor-beta 2 (TGF-beta2) is a hallmark of various malignant tumors including pancreatic carcinoma, malignant glioma, metastasizing melanoma, and metastatic colorectal carcinoma. This is due to the pivotal role of TGF-beta2 as it regulates key mechanisms of tumor development, namely immunosuppression, metastasis, angiogenesis, and proliferation. The antisense technology is an innovative technique offering a targeted approach for the treatment of different highly aggressive tumors and other diseases. Antisense oligonucleotides are being developed to inhibit the production of disease-causing proteins at the molecular level. The immunotherapeutic approach with the phosphorothioate oligodeoxynucleotide AP 12009 for the treatment of malignant tumors is based on the specific inhibition of TGF-beta2.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 159.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 209.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 209.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agrawal S, Temsamani J, Tang JY (1991) Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A 88:7595–7599

    Article  PubMed  CAS  Google Scholar 

  2. Agrawal S, Temsamani J, Galbraith W, Tang J (1995) Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 28:7–16

    PubMed  CAS  Google Scholar 

  3. Agrawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, Roskey A, Channavajjala L, Saxinger C, Zhang R (1997) Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc Natl Acad Sci U S A 94:2620–2625

    Article  PubMed  CAS  Google Scholar 

  4. Akhtar S, Agrawal S (1997) In vivo studies with antisense oligonucleotides. Trends Pharmacol Sci 18:12–18

    Article  PubMed  CAS  Google Scholar 

  5. Akhurst RJ, Derynck R (2001) TGF-beta signaling in cancer—a double-edged sword. Trends Cell Biol 11:S44–51

    PubMed  CAS  Google Scholar 

  6. Annes JP, Munger JS, Rifkin DB (2003) Making sense of latent TGFbeta activation. J Cell Sci 116:217–224

    Article  PubMed  CAS  Google Scholar 

  7. Auerbach M, Wampler GL, Lokich JJ, Fryer D, Fryer JG, Ahlgren JD (1997) Treatment of advanced pancreatic carcinoma with a combination of protracted infusional 5-fluorouracil and weekly carboplatin: a Mid-Atlantic Oncology Program Study. Ann Oncol 8:439–444

    Article  PubMed  CAS  Google Scholar 

  8. Blobe GC, Schiemann WP, Pepin MC, Beauchemin M, Moustakas A, Lodish HF, O‘Connor-McCourt MD (2001) Functional roles for the cytoplasmic domain of the type III transforming growth factor beta receptor in regulating transforming growth factor beta signaling. J Biol Chem 276:24627–24637

    Article  PubMed  CAS  Google Scholar 

  9. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91:2076–2080

    Article  PubMed  CAS  Google Scholar 

  10. Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I, Fontana A (1989) Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 143:3222–3229

    PubMed  CAS  Google Scholar 

  11. Bogdahn U, Oliushine VE, Parfenov VE, Kunst M, Mahapatra AK, Sastry KVR, Venkataramana KN, Jachimczak P, Hau P, Schlingensiepen KH (2006) Results of G004, a phase IIb study in recurrent glioblastoma patients with the TGF-b2 targeted compound AP 12009. J Clin Oncol, ASCO Annual Meeting Proceedings 24:1553

    Google Scholar 

  12. Braasch DA, Corey DR (2002) Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochemistry 41:4503–4510

    Article  PubMed  CAS  Google Scholar 

  13. Brysch W, Schlingensiepen KH (1994) Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents. Cell Mol Neurobiol 14:557–568

    Article  PubMed  CAS  Google Scholar 

  14. Burgess TL, Fisher EF, Ross SL, Bready JV, Qian YX, Bayewitch LA, Cohen AM, Herrera CJ, Hu SS, Kramer TB, et al. (1995) The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci U S A 92:4051–4055

    Article  PubMed  CAS  Google Scholar 

  15. Cardenes HR, Chiorean EG, Dewitt J, Schmidt M, Loehrer P (2006) Locally advanced pancreatic cancer: current therapeutic approach. Oncologist 11:612–623

    Article  PubMed  CAS  Google Scholar 

  16. Choudhury A, Moniaux N, Ulrich AB, Schmied BM, Standop J, Pour PM, Gendler SJ, Hollingsworth MA, Aubert JP, Batra SK (2004) MUC4 mucin expression in human pancreatic tumours is affected by organ environment: the possible role of TGFbeta2. Br J Cancer 90:657–664

    Article  PubMed  CAS  Google Scholar 

  17. Coppelli FM, Grandis JR (2005) Oligonucleotides as anticancer agents: from the benchside to the clinic and beyond. Curr Pharm Des 11:2825–2840

    Article  PubMed  CAS  Google Scholar 

  18. Crooke ST (1999) Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta 1489:31–44

    PubMed  CAS  Google Scholar 

  19. Crookston KP, Webb DJ, Wolf BB, Gonias SL (1994) Classification of alpha 2-macroglobulin-cytokine interactions based on affinity of noncovalent association in solution under apparent equilibrium conditions. J Biol Chem 269:1533–1540

    PubMed  CAS  Google Scholar 

  20. Danielpour D, Sporn MB (1990) Differential inhibition of transforming growth factor beta 1 and beta 2 activity by alpha 2-macroglobulin. J Biol Chem 265:6973–6977

    PubMed  CAS  Google Scholar 

  21. Dean NM, Bennett CF (2003) Antisense oligonucleotide-based therapeutics for cancer. Oncogene 22:9087–9096

    Article  PubMed  CAS  Google Scholar 

  22. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425:577–584

    Article  PubMed  CAS  Google Scholar 

  23. Dumont N, Arteaga CL (2000) Transforming growth factor-beta and breast cancer: tumor promoting effects of transforming growth factor-beta. Breast Cancer Res 2:125–132

    Article  PubMed  CAS  Google Scholar 

  24. Eckstein F (1983) Phosphorothioate analogues of nucleotides—tools for the investigation of biochemical processes. Angew Chem Int Ed Engl 22:423–506

    Article  Google Scholar 

  25. Frankel B, Longo SL, Ryken TC (1999) Human astrocytomas co-expressing Fas and Fas ligand also produce TGFbeta2 and Bcl-2. J Neurooncol 44:205–212

    Article  PubMed  CAS  Google Scholar 

  26. Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, Gold LI, Korc M (1993) Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105:1846–1856

    PubMed  CAS  Google Scholar 

  27. Gardlik R, Palffy R, Hodosy J, Lukacs J, Turna J, Celec P (2005) Vectors and delivery systems in gene therapy. Med Sci Monit 11:RA110–RA121

    Google Scholar 

  28. Geary RS, Yu RZ, Levin AA (2001) Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Investig Drugs 2:562–573

    PubMed  CAS  Google Scholar 

  29. Gorelik L, Flavell RA (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7:1118–1122

    Article  PubMed  CAS  Google Scholar 

  30. Hau P, Stockhammer G, Kunst M, Mahapatra AK, Sastry KVR, Parfenov V, Leshinsky V, Jachimczak P, Bogdahn U, Schlingensiepen K-H (2006) Results of G004, a phase IIb actively controlled clinical trial with the TGF-b2 targeted compound AP 12009 for recurrent anaplastic astrocytoma. J Clin Oncol, ASCO Annual Meeting Proceedings 24:1566

    Google Scholar 

  31. Henry SP, Bolte H, Auletta C, Kornbrust DJ (1997) Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Toxicology 120:145–155

    Article  PubMed  CAS  Google Scholar 

  32. Jachimczak P, Bogdahn U, Schneider J, Behl C, Meixensberger J, Apfel R, Dorries R, Schlingensiepen KH, Brysch W (1993) The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg 78:944–951

    PubMed  CAS  Google Scholar 

  33. Jachimczak P, Hessdorfer B, Fabel-Schulte K, Wismeth C, Brysch W, Schlingensiepen KH, Bauer A, Blesch A, Bogdahn U (1996) Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int J Cancer 65:332–337

    Article  PubMed  CAS  Google Scholar 

  34. Janji B, Melchior C, Gouon V, Vallar L, Kieffer N (1999) Autocrine TGF-beta-regulated expression of adhesion receptors and integrin-linked kinase in HT-144 melanoma cells correlates with their metastatic phenotype. Int J Cancer 83:255–262

    Article  PubMed  CAS  Google Scholar 

  35. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun M (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30

    PubMed  Google Scholar 

  36. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130

    PubMed  Google Scholar 

  37. Kjellman C, Olofsson SP, Hansson O, Von Schantz T, Lindvall M, Nilsson I, Salford LG, Sjogren HO, Widegren B (2000) Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 89:251–258

    Article  PubMed  CAS  Google Scholar 

  38. Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709–760

    Article  PubMed  CAS  Google Scholar 

  39. Kurreck J (2003) Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 270:1628–1644

    Article  PubMed  CAS  Google Scholar 

  40. Lahn M, Kloeker S, Berry BS (2005) TGF-beta inhibitors for the treatment of cancer. Expert Opin Investig Drugs 14:629–643

    Article  PubMed  CAS  Google Scholar 

  41. Lee Y, Vassilakos A, Feng N, Jin H, Wang M, Xiong K, Wright J, Young A (2006) GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors. Int J Oncol 28:469–478

    PubMed  CAS  Google Scholar 

  42. Levin AA (1999) A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1489:69–84

    PubMed  CAS  Google Scholar 

  43. Levin AA, Monteith DK, Leeds JM, Nicklin PL, Geary RS, Butler M, Templin MV, Henry SP (1998) Toxicity of oligonucleotide therapeutic agents. In: Crooke ST (ed) Antisense research and application. Springer, Berlin Heidelberg New York, pp 169–215

    Google Scholar 

  44. Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. Lancet 363:1049–1057

    Article  PubMed  CAS  Google Scholar 

  45. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA (2006) Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24:99–146

    Article  PubMed  CAS  Google Scholar 

  46. Lieberman DM, Laske DW, Morrison PF, Bankiewicz KS, Oldfield EH (1995) Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 82:1021–1029

    Article  PubMed  CAS  Google Scholar 

  47. Liu Q, Ling TY, Shieh HS, Johnson FE, Huang JS, Huang SS (2001) Identification of the high affinity binding site in transforming growth factor-beta involved in complex formation with alpha 2-macroglobulin. Implications regarding the molecular mechanisms of complex formation between alpha 2-macroglobulin and growth factors, cytokines, and hormones. J Biol Chem 276:46212–46218

    Article  PubMed  CAS  Google Scholar 

  48. Lowenfels AB, Maisonneuve P (2006) Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 20:197–209

    Article  PubMed  Google Scholar 

  49. Lysik MA, Wu-Pong S (2003) Innovations in oligonucleotide drug delivery. J Pharm Sci 92:1559–1573

    Article  PubMed  CAS  Google Scholar 

  50. Mahato RI (2005) Biomaterials for delivery and targeting of proteins and nucleic acids. CRC Press, Boca Raton

    Google Scholar 

  51. Mahato RI, Ye Z, Guntaka RV (2005) Antisense and antigene oligonucleotides: structure, stability and delivery. In: Mahato RI (ed) Biomaterials for delivering and targeting of proteins and nucleic acids. CRC Press, Boca Raton, pp 569–600

    Google Scholar 

  52. Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades HN (1992) Effect of the expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J Neurosurg 76:799–804

    PubMed  CAS  Google Scholar 

  53. Miller PS, McParland KB, Jayaraman K, Ts‘o PO (1981) Biochemical and biological effects of nonionic nucleic acid methylphosphonates. Biochemistry 20:1874–1880

    Article  PubMed  CAS  Google Scholar 

  54. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S, Au H, Ding J, Christy-Bittel J, Parulekar W (2005) Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 23:16S

    Google Scholar 

  55. Moustakas A, Pardali K, Gaal A, Heldin CH (2002) Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol Lett 82:85–91

    Article  PubMed  CAS  Google Scholar 

  56. Murphy-Ullrich JE, Poczatek M (2000) Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 11:59–69

    Article  PubMed  CAS  Google Scholar 

  57. Nygaard SJ, Haugland HK, Laerum OD, Lund-Johansen M, Bjerkvig R, Tysnes OB (1998) Dynamic determination of human glioma invasion in vitro. J Neurosurg 89:441–447

    PubMed  CAS  Google Scholar 

  58. O‘Connor-McCourt MD, Wakefield LM (1987) Latent transforming growth factor-beta in serum. A specific complex with alpha 2-macroglobulin. J Biol Chem 262:14090–14099

    PubMed  CAS  Google Scholar 

  59. Oeklue R, Hesketh R (2000) The latent transforming growth factor beta binding protein (LTBP) family. Biochem J 352:601–610

    Article  Google Scholar 

  60. Oft M, Heider KH, Beug H (1998) TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 8:1243–1252

    Article  PubMed  CAS  Google Scholar 

  61. Piek E, Heldin CH, Ten Dijke P (1999) Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J 13:2105–2124

    PubMed  CAS  Google Scholar 

  62. Plank C, Mechtler K, Szoka FC Jr, Wagner E (1996) Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther 7:1437–1446

    Article  PubMed  CAS  Google Scholar 

  63. Roberts AB (1998) Molecular and cell biology of TGF-beta. Miner Electrolyte Metab 24:111–119

    Article  PubMed  CAS  Google Scholar 

  64. Roehr B (1998) Fomivirsen approved for CMV retinitis. J Int Assoc Physicians AIDS Care 4:14–16

    PubMed  CAS  Google Scholar 

  65. Schlingensiepen KH, Schlingensiepen R, Kunst M, Klinger I, Gerdes W, Seifert W, Brysch W (1993) Opposite functions of jun-B and c-jun in growth regulation and neuronal differentiation. Dev Genet 14:305–312

    Article  PubMed  CAS  Google Scholar 

  66. Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B, Jachimczak P (2006) Targeted tumor therapy with the TGF-b2 antisense compound AP 12009. Cytokine Growth Factor Rev 17:129–139

    Article  PubMed  CAS  Google Scholar 

  67. Schlingensiepen R, Brysch W, Schlingensiepen KH (1997) Antisense: from technology to therapy: lab manual and textbook. Blackwell Science, Berlin

    Google Scholar 

  68. Schlingensiepen R, Goldbrunner M, Szyrach MN, Stauder G, Jachimczak P, Bogdahn U, Schulmeyer F, Hau P, Schlingensiepen KH (2005) Intracerebral and intrathecal infusion of the TGF-beta2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety. Oligonucleotides 15:94–104

    Article  PubMed  CAS  Google Scholar 

  69. Shaw JP, Kent K, Bird J, Fishback J, Froehler B (1991) Modified deoxyoligonucleotides stable to exonuclease degradation in serum. Nucleic Acids Res 19:747–750

    Article  PubMed  CAS  Google Scholar 

  70. Shen ZJ, Kim SK, Lee YS, Lee JW, Moon BJ (1999) Inhibition of transforming growth factor-beta 2 expression with phosphorothioate antisense oligonucleotides in U937 cells. Bioorg Med Chem Lett 9:13–18

    Article  PubMed  CAS  Google Scholar 

  71. Siech M, Schlosser W, Beger HG (2001) Modern techniques for operation for chronic pancreatitis and pancreatic carcinoma and postoperative consequences. Pancreatology 1:1–8

    Article  Google Scholar 

  72. Stein CA, Tonkinson JL, Zhang LM, Yakubov L, Gervasoni J, Taub R, Rotenberg SA (1993) Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry 32:4855–4861

    Article  PubMed  CAS  Google Scholar 

  73. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  PubMed  CAS  Google Scholar 

  74. Sung RS, Qin L, Bromberg JS (2001) TNFalpha and IFNgamma induced by innate anti-adenoviral immune responses inhibit adenovirus-mediated transgene expression. Mol Ther 3:757–767

    Article  PubMed  CAS  Google Scholar 

  75. Tari AM, Lopez-Berestein G (2001) Cellular uptake of antisense oligonucleotides. Curr Opin Investig Drugs 2:1450–1453

    PubMed  CAS  Google Scholar 

  76. Theodosopoulos PV, Lamborn KR, Malec M, et al. (2001) Temozolomide in the treatment of recurrent malignant glioma. Proc ASCO, San Francisco

    Google Scholar 

  77. Tidd DM, Warenius HM (1989) Partial protection of oncogene, anti-sense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups. Br J Cancer 60:343–350

    PubMed  CAS  Google Scholar 

  78. Wakefield LM, Roberts AB (2002) TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 12:22–29

    Article  PubMed  CAS  Google Scholar 

  79. Weller M, Fontana A (1995) The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res Brain Res Rev 21:128–151

    Article  PubMed  CAS  Google Scholar 

  80. Wickstrom E (1986) Oligodeoxynucleotide stability in subcellular extracts and culture media. J Biochem Biophys Methods 13:97–102

    Article  PubMed  CAS  Google Scholar 

  81. Yang Y, Wilson JM (1995) Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol 155:2564–2570

    PubMed  CAS  Google Scholar 

  82. Yaswen P, Stampfer MR, Ghosh K, Cohen JS (1993) Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res Dev 3:67–77

    PubMed  CAS  Google Scholar 

  83. Yingling JM, Blanchard KL, Sawyer JS (2004) Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 3:1011–1022

    Article  PubMed  CAS  Google Scholar 

  84. Yung WK (2000) Temozolomide in malignant gliomas. Semin Oncol 27:27–34

    PubMed  CAS  Google Scholar 

  85. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588–593

    Article  PubMed  CAS  Google Scholar 

  86. Zamecnik P, Aghajanian J, Zamecnik M, Goodchild J, Witman G (1994) Electron micrographic studies of transport of oligodeoxynucleotides across eukaryotic cell membranes. Proc Natl Acad Sci U S A 91:3156–3160

    Article  PubMed  CAS  Google Scholar 

  87. Zamecnik PC, Stephenson ML (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A 75:280–284

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Antisense Pharma GmbH, Josef-Engert-Str. 9, 93053, Regensburg, Germany

    Karl-Hermann Schlingensiepen, Birgit Fischer-Blass, Susanne Schmaus & Sylvia Ludwig

Authors
  1. Karl-Hermann Schlingensiepen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Birgit Fischer-Blass
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susanne Schmaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sylvia Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schlingensiepen, KH., Fischer-Blass, B., Schmaus, S., Ludwig, S. (2008). Antisense Therapeutics for Tumor Treatment: The TGF-beta2 Inhibitor AP 12009 in Clinical Development Against Malignant Tumors. In: Pancreatic Cancer. Recent Results in Cancer Research, vol 177. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-71279-4_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-71279-4_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-71266-4

  • Online ISBN: 978-3-540-71279-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation